BTEB1 Inhibitors
The chemical class known as BTEB1 inhibitors encompasses a diverse array of compounds targeting various signaling pathways intricately linked to the modulation of BTEB1 activity. Wortmannin, Rapamycin, and LY294002 act as potent inhibitors of the PI3K/Akt pathway, disrupting the phosphorylation events critical for Akt activation and indirectly modulating BTEB1. SB-203580 and SP600125 target the p38 MAPK and JNK pathways, respectively, showcasing how inhibition of these pathways can impact BTEB1. PD98059 and U0126, MEK inhibitors, directly modulate the MAPK pathway, influencing BTEB1 through the disruption of downstream signaling events.
Furthermore, SB216763, SB431542, and AZD5363 act on the Wnt, TGF-β, and Akt pathways, respectively, directly or indirectly modulating BTEB1 activity. VX-745, a JAK inhibitor, and SB590885, a PLK inhibitor, showcase the specificity of inhibitors, targeting the JAK/STAT pathway and Polo-like kinase, respectively, and impacting cellular processes linked to BTEB1. These BTEB1 inhibitors collectively highlight the intricate network of signaling pathways and cellular processes that converge on BTEB1, illustrating the potential for targeted chemical interventions in the regulatory network governing the activity of this transcriptional regulator. The specificity of these inhibitors in influencing defined pathways provides a foundation for understanding the molecular mechanisms underlying BTEB1 modulation and offers insights into potential strategies for precise cellular control in the context of BTEB1-mediated processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a potent PI3-kinase inhibitor, directly influences the PI3K/Akt pathway, a signaling cascade intricately linked to BTEB1. By binding irreversibly to PI3-kinase, Wortmannin disrupts the phosphorylation events critical for Akt activation, thereby indirectly modulating BTEB1 through the attenuation of the PI3K/Akt signaling axis. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, impacts the mTOR pathway, which converges with the PI3K/Akt pathway. Through allosteric binding to mTORC1, Rapamycin disrupts downstream signaling events, ultimately suppressing the PI3K/Akt pathway. C | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a reversible PI3-kinase inhibitor, directly interferes with the PI3K/Akt pathway. By competitively binding to the ATP-binding pocket of PI3-kinase, LY294002 impedes the phosphorylation cascade that activates Akt. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB-203580, a p38 MAPK inhibitor, targets the p38 MAPK pathway. Given that the p38 MAPK pathway intersects with multiple cellular signaling networks, including those involving BTEB1, inhibition of p38 MAPK by SB-203580 indirectly influences BTEB1 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, directly affects the JNK signaling pathway. As BTEB1 is intricately connected to JNK-mediated pathways, SP600125 serves as a key tool in modulating the cellular processes regulated by BTEB1. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, a MEK inhibitor, operates on the MAPK pathway by specifically inhibiting MEK1 and MEK2. The MAPK pathway intersects with cellular processes involving BTEB1, and PD98059, by dampening the MAPK pathway, indirectly modulates BTEB1 activity. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
SB216763, a selective GSK-3 inhibitor, operates on the Wnt pathway. As the Wnt pathway intersects with BTEB1-related signaling networks, SB216763 serves as a crucial modulator of BTEB1 activity. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542, a TGF-β receptor inhibitor, directly impacts the TGF-β signaling pathway. Since TGF-β signaling is intricately connected to BTEB1-mediated processes, SB431542 serves as a key modulator of BTEB1 activity. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363, an Akt inhibitor, directly targets the PI3K/Akt pathway. As BTEB1 is intricately linked to PI3K/Akt-mediated processes, AZD5363 serves as a potent modulator of BTEB1 activity. By inhibiting Akt, AZD5363 disrupts the phosphorylation events critical for downstream signaling, ultimately influencing cellular processes regulated by BTEB1. | ||||||
VX 745 | 209410-46-8 | sc-361401 sc-361401A | 10 mg 50 mg | $183.00 $842.00 | 4 | |
VX-745, a selective JAK inhibitor, directly influences the JAK/STAT pathway. Since the JAK/STAT pathway intersects with cellular processes involving BTEB1, VX-745 serves as a crucial modulator of BTEB1 activity. | ||||||